AtriCure, Inc. (NASDAQ:ATRC) Stock Rated "Moderate Buy" by Wall Street Brokerages

Key Points

• Wall Street maintains a moderately bullish view: Twelve brokerages rate AtriCure “Moderate Buy,” including seven buys and one strong buy. The average 12-month price target is $53.30, with recent targets ranging from $52 to $65.
• AtriCure reported quarterly EPS of $0.18 and revenue of $153.6 million, exceeding the $151.8 million consensus revenue estimate. Analysts expect approximately $0.29 in EPS for the current fiscal year.
• The stock opened at $58.38, near its 52-week high of $61.70, while insiders have sold 74,868 shares worth $3.32 million over the past three months. Institutional investors and hedge funds own approximately 99.11% of the company.

Shares of AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) have been assigned an average rating of "Moderate Buy" from the twelve brokerages that are covering the firm, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $53.30.

A number of research analysts have recently commented on ATRC shares. Weiss Ratings upgraded AtriCure from a "sell (d+)" rating to a "hold (c-)" rating in a report on Wednesday, August 19th. Raymond James Financial set a $52.00 target price on AtriCure in a research note on Tuesday, July 21st. BTIG Research upped their price target on AtriCure from $45.00 to $55.00 and gave the company a "buy" rating in a report on Monday, August 24th. Stifel Nicolaus set a $65.00 price target on shares of AtriCure in a research note on Thursday, September 17th. Finally, Needham & Company LLC raised their price objective on shares of AtriCure from $45.00 to $64.00 and gave the stock a "buy" rating in a report on Wednesday, September 2nd.

AtriCure Price Performance

Shares of ATRC opened at $58.38 on Friday. AtriCure has a twelve month low of $25.36 and a twelve month high of $61.70. The firm's fifty day simple moving average is $47.23 and its 200-day simple moving average is $35.45. The firm has a market capitalization of $2.97 billion, a price-to-earnings ratio of 278.01 and a beta of 1.26. The company has a current ratio of 4.22, a quick ratio of 3.19 and a debt-to-equity ratio of 0.14.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 EPS for the quarter. The firm had revenue of $153.60 million during the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter in the previous year, the firm posted ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities analysts forecast that AtriCure will post 0.29 EPS for the current fiscal year.

Insider Transactions at AtriCure

In other AtriCure news, insider Karl S. Dahlquist sold 9,370 shares of the company's stock in a transaction on Monday, August 24th. The shares were sold at an average price of $48.89, for a total value of $458,099.30. Following the completion of the transaction, the insider owned 87,319 shares in the company, valued at $4,269,025.91. This represents a 9.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, insider Justin J. Noznesky sold 6,182 shares of the firm's stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $38.80, for a total value of $239,861.60. Following the transaction, the insider directly owned 100,219 shares in the company, valued at approximately $3,888,497.20. The trade was a 5.81% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 74,868 shares of company stock worth $3,317,897. Insiders own 4.00% of the company's stock.

Institutional Trading of AtriCure

Large investors have recently made changes to their positions in the company. Harbor Investment Advisory LLC purchased a new stake in shares of AtriCure during the second quarter worth approximately $40,000. Allworth Financial LP purchased a new position in AtriCure in the 2nd quarter valued at $43,000. Integrated Wealth Concepts LLC purchased a new position in AtriCure in the 2nd quarter valued at $46,000. Fifth Third Bancorp acquired a new position in AtriCure in the 1st quarter valued at $51,000. Finally, Global Retirement Partners LLC acquired a new position in AtriCure in the 2nd quarter valued at $52,000. 99.11% of the stock is owned by institutional investors and hedge funds.

About AtriCure

AtriCure, Inc NASDAQ: ATRC is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.